newsfilter
← Earnings
Earnings Releases·

Kyverna Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported cash and marketable securities of $170.6 million as of September 30, 2026, down from $279.3 million at year-end 2025, with an operating runway extending into 2028 inclusive of the Oxford Finance loan facility.
  • Net loss for the quarter was $41.9 million ($0.68 per share) compared to $36.8 million ($0.85 per share) in Q3 2025; year-to-date net loss narrowed to $120.0 million ($1.96 per share) from $123.6 million ($2.85 per share) in 2025.
  • Completed rolling BLA submission for miv-cel in stiff person syndrome (SPS) seeking priority review under RMAT designation; anticipates FDA approval and commercial launch in 2027.
  • Deprioritized the KYV-102 program to focus on late-stage neurologic indications with miv-cel, which has received three FDA RMAT designations for SPS, gMG, and naSPMS.
  • Management is advancing commercial readiness for a potential 2027 launch by hiring key leadership, initiating field infrastructure, and building patient support networks.
Company
KYVERNA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology